Cocrystal Pharma Announces Nasdaq Closing Bell Ceremony
June 04 2018 - 8:00AM
Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the
“Company”), a clinical stage biotechnology company discovering and
developing novel antiviral therapeutics that target the
replication machinery of hepatitis viruses, influenza viruses
and noroviruses, announced today that Dr. Gary Wilcox, Vice
Chairman and Chief Executive Officer of Cocrystal, will ring the
Nasdaq Stock Market Closing Bell on Wednesday, June 6, 2018. The
bell ringing ceremony celebrates the Company’s recent uplisting to
The Nasdaq Capital Market, the progress of its Phase 2a study of
its lead product candidate, CC-31244, for the treatment of
hepatitis C (HepC) as well as the progress of the influenza
program.
A
live webcast of the ceremony will be available
at: https://livestream.com/nasdaq/live. The Company's
executive management team, family members and other supporters will
join in the ceremony.
Dr. Wilcox commented, “We are honored to be
included on The Nasdaq Capital Market along with many leading life
sciences companies bringing innovative therapies to patients in
need. We are grateful for the opportunity to acknowledge our
corporate and clinical progress, and importantly, what we believe
will be an exciting future for Cocrystal with the ringing of the
Nasdaq closing bell.”
CC-31244, the Company’s lead product in
development for HepC, is an investigational, oral, potent,
broad-spectrum replication inhibitor called an NNI. It has a high
barrier to drug resistance designed and developed using the
Company's proprietary structure-based drug discovery technology. It
is a highly potent, broad spectrum non-nucleoside inhibitor that is
active against all genotypes (1-6).
The Company recently announced that its
Investigational New Drug (IND) application submitted to the FDA is
now open and the Company is cleared to initiate its Phase 2a
clinical study evaluating CC-31244 for the treatment of
HepC-infected individuals. The Company expects to initiate patient
enrollment and dosing in the Phase 2a study evaluating CC-31244 for
the treatment of HepC this quarter.
In addition to the Company’s HepC clinical
program, Cocrystal is developing novel, broad spectrum influenza
antivirals that are specifically designed to be effective against
all strains of the influenza virus and to have a high barrier to
resistance due to the way it targets the virus. CC-42344, its lead
molecule, is a highly potent PB2 inhibitor and shows a favorable
pharmacokinetic and safety profile. The lead candidate for
influenza has advanced to IND-enabling studies.
About Nasdaq
Nasdaq is a leading provider of trading,
clearing, exchange technology, listing, information and public
company services across six continents. Through its diverse
portfolio of solutions, Nasdaq enables clients to plan, optimize
and execute their business vision with confidence, using proven
technologies that provide transparency and insight for navigating
today's global capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 85
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to approximately 3,800 listed
companies with a market value of $10.1 trillion and nearly 18,000
corporate clients. To learn more, visit: business.nasdaq.com.
About Cocrystal Pharma,
Inc.
Cocrystal Pharma, Inc. is a clinical stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication machinery of hepatitis
viruses, influenza viruses, and noroviruses. Cocrystal employs
unique structure-based technologies and Nobel Prize winning
expertise to create first- and best-in-class antiviral drugs.
CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside
replication inhibitor of HepC. Phase 1b studies in HepC infected
patients showed the largest reduction in viral load of any
non-nucleoside inhibitor tested to date. The next step for CC-31244
is clinical trials as part of a cocktail for ultra-short therapy of
2 to 6 weeks. The lead candidate for influenza has advanced to
IND-enabling studies. It is effective in animal models against both
the pandemic and seasonal strains of influenza. In addition, the
Company has a pipeline of promising early preclinical programs. Two
private investors own approximately 48% of the Company. Corporate
investors include OPKO Health, Inc., Brace Pharma Capital, LLC and
Teva Pharmaceuticals Industries, Ltd. For further information about
Cocrystal, please visit www.cocrystalpharma.com.
Forward-Looking Statements This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including our expectations regarding the commencement of the Phase
2a study for our Hepatis C product. The words "believe," "may,"
"estimate," "continue," "anticipate," "intend," "should," "plan,"
"could," "target," "potential," "is likely," "will," "expect" and
similar expressions, as they relate to us, are intended to identify
forward-looking statements. We have based these forward-looking
statements largely on our current expectations and projections
about future events. Some or all of the events anticipated by these
forward-looking statements may not occur. Important factors that
could cause actual results to differ from those in the
forward-looking statements include the availability of products
manufactured by third parties, the ability of the clinical research
organization conducting studies to recruit subjects and obtaining
regulatory clearance. Further information on our risk factors is
contained in our filings with the SEC, including the Prospectus
Supplement dated April 30, 2018, and our Annual Report on Form 10-K
for the year ended December 31, 2017. Any forward-looking statement
made by us herein speaks only as of the date on which it is made.
Factors or events that could cause our actual results to differ may
emerge from time to time, and it is not possible for us to predict
all of them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
law.
Investor Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
(833) 475-8247
COCP@jtcir.com
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Apr 2023 to Apr 2024